Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 275 Shoreline Drive, Suite 500 REDWOOD CITY CA 94065 |
Tel: | N/A |
Website: | https://www.rezolutebio.com |
IR: | See website |
Key People | ||
Nevan Charles Elam Acting Chairman of the Board, Chief Executive Officer | Daron Evans Chief Financial Officer | Brian K. Roberts Chief Medical Officer |
Business Overview |
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company's lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage. |
Financial Overview |
For the six months ended 31 December 2023, Rezolute Inc revenues was not reported. Net loss increased 22% to $28.4M. Higher net loss reflects Research and development - Balancing val increase of 32% to $22.3M (expense), General and administrative - Balancing increase of 23% to $4.8M (expense), Stock-based Compensation in R&D increase of 5% to $1.7M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.46 to -$0.55. |
Employees: | 51 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $27.38M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$62.45M as of Dec 31, 2023 |
Net annual income (TTM): | -$56.83M as of Dec 31, 2023 |
Free cash flow (TTM): | -$53.00M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 40,127,647 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |